Neuravi has received CE mark approval for newly available enhancements to its EmboTrap stent retriever platform, the EmboTrap II revascularisation device. The company will now launch the product in Europe, according to a press release.
The US Food and Drug Administration (FDA) has allowed marketing of two Trevo (Stryker Neurovascular) clot retrieval devices as an initial therapy for ischaemic strokes to reduce paralysis, speech difficulties and other stroke disabilities.
People with non-small cell lung cancer, whose disease has spread to the brain, could be spared potentially harmful whole brain radiotherapy, according to new research published in The Lancet. The phase 3 randomised trial found that whole brain radiotherapy had no beneficial effect on length or quality of survival over treatment with steroids and other supportive care.
BALT International has announced that it has acquired Blockade Medical LLC, a privately held company focused on the development of catheter based therapeutic devices for the treatment of cerebral aneurysms. The terms of the acquisition were not disclosed.
A Wichita State University nursing faculty member, Wendy Dusenbury, has been invited to join an inaugural group of practitioners at the University of Tennessee to help test a one-of-a-kind mobile stroke unit. The specialised vehicle is the world’s largest mobile stroke unit and contains the most advanced computed tomography (CT) imaging capabilities ever in a mobile setting.
New University of British Columbia (Vancouver, Canada) research has found that amplified electroencephalograms can produce diagnostic results of cortical spreading depression that are comparable to placing electrodes directly to the surface of the brain, if a specially designed amplifier is used in tandem.
Data from the STRATIS registry presented at the Society of NeuroInterventional Surgery annual meeting (SNIS; 25–28 July, Boston, USA) show that the transfer of stroke patients from one hospital to another is responsible for delays in revascularisation and suggest that there may be a place for bypassing closer hospitals for one that is capable of administering mechanical thrombectomy. The data were presented by Michael Froehler (Vanderbilt University Medical Center, Nashville, USA).
Diseased blood vessels in the brain itself may contribute more significantly to Alzheimer’s disease dementia than was previously believed, according to new study results published in The Lancet Neurology.
A new study, published in The Journal of Pain, has shown that transcranial magnetic stimulation (rTMS) administered to the scalp can stimulate the brain and provide significant reductions in phantom limb pain
InSightec has signed a strategic agreement with Siemens Healthineers. The strategic collaboration will involve the development of compatibility between Exablate Neuro and Siemens 1.5T and 3T clinical magnetic resonance imaging systems, Magnetom Aera and Skyra.
Medtronic has received CE mark for SureTune2 software, which is designed to provide patient-specific visualisation to help physicians make decisions on how to program their patient’s deep brain stimulation therapy. SureTune2 is currently not approved in the USA.
Boston Scientific Corporation has acquired Cosman Medical a privately-held manufacturer of radiofrequency ablation systems. According to a press release, the Cosman Medical team and products will become part of the Boston Scientific Neuromodulation business.
The US Food and Drug Administration FDA has allowed marketing of two Trevo Stryker Neurovascular clot retrieval devices as an initial therapy for ischaemic strokes to reduce paralysis, speech difficulties and other stroke disabilities.
Codman Neuro, part of DePuy Synthes Companies of Johnson & Johnson, has entered into an agreement with InNeuroCo for exclusive US and European distribution rights for intermediate catheters that are designed to enable minimally invasive treatment of haemorrhagic stroke. The announcement was made at the Society of NeuroInterventional Surgery (SNIS) 13th Annual Meeting.
According to an email from the consumer watchdog, the document is intended to clarify “how the FDA determines that real-world data may be sufficient for use in premarket and postmarket regulatory decisions, without changing the evidentiary standards we use to make those decisions.”
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos